Press release
Hope for Rapid, Non-Invasive Endometriosis Diagnosis
New diagnostic test for endometriosis, the ENDOSURE test, offers decision support to clinicians with 99.87% accurate results in less than an hour, could transform women's healthcareEDMONTON, AB - In a groundbreaking development for women's health featured on Global News Calgary by journalist Jayme Doll on March 12, 2025, the ENDOSURE test emerges as a beacon of hope for millions suffering from undiagnosed endometriosis in. This non-invasive diagnostic tool promises to deliver results with unprecedented speed and accuracy, slashing the current 5.3-year average diagnostic delay in Canada to less than an hour. Jayme Doll's reporting for Global News is available at: https://globalnews.ca/news/11074941/lets-talk-about-it-period/
Endometriosis, a condition affecting approximately 1 in 10 women, has long been challenging to diagnose, often requiring invasive procedures and prolonged wait times. The ENDOSURE test, however, offers a paradigm shift in endometriosis detection with accurate, rapid, objective results obtained non-invasively.
Despite its potential, the ENDOSURE test remains largely inaccessible to patients, pending recognition and adoption by the healthcare system.
"It's just existential dread," shares Rose Plican, a 19-year-old endometriosis patient. "Wrapped in a blanket, waiting and wishing away the pain. I just physically can't get out of bed. I can't move. So, it's stopped me in a lot of ways from sort of just living." Rose's story echoes the struggles of countless women facing years-long waitlists for specialists and invasive diagnostic procedures.
Her mother, Carolyn Plican, a patient advocate, emphasizes the psychological impact of a diagnosis: "Suddenly when you're diagnosed, you know it's not in your head. It gives you permission to find better strategies to manage pain and get on a wait list for a laparoscopy to have it excised if it's affecting you really badly."
Dr. Mary Ellen Haggerty supports the ENDOSURE test, stating, "It's a decision help. I think it's really good to make those sorts of diagnosis early. This confirms the diagnosis without being an invasive procedure."
The ball is now in the court of healthcare decision-makers. Will they recognize the value of using the ENDOSURE test for early diagnosis, which has been authorized for sale by Health Canada since 2021, as a significant step towards helping women in debilitating pain? As the medical community debates the role of this new technology, advocates like Carolyn Plican continue to advocate for better access to the ENDOSURE test with its potential to revolutionize endometriosis care by:
* Reducing diagnostic delays
* Minimizing invasive procedures
* Improving patient quality of life
* Potentially lowering healthcare costs long-term
If you are advocating for yourself or someone you love to access earlier diagnostic testing for endometriosis because of pelvic pain, period pain, or infertility, please join the ENDOSURE waitlist at EndoDiagnosis [https://endodiagnosis.com/hope-for-rapid-non-invasive-endometriosis-diagnosis/].
For more information about the ENDOSURE test please contact:
Carolyn Plican
https://endodiagnosis.com/
1-833-439-3636
at hello@endodiagnosis.com [mailto:hello@endodiagnosis.com]
EndoDiagnosis, Inc
EndoDiagnosis, Inc was spearheaded by a Canadian team of healthcare professions to bring rapid diagnostic tools and other adjuncts that expedite endometriosis care. The ENDOSURE Test is a non-invasive, 99% accurate diagnostic test for endometriosis, providing instant results in 30-minutes. ENDOSURE provides clinical evidence for practitioners who suspect endometriosis in their patients with dysmenorrhea and/or chronic pelvic pain, infertility & miscarriage or for pre pregnancy screening
EndoDiagnosis, Inc became the Manufacturer's Agent for ENDOSURE in Canada in December 2024. ENDOSURE has been authorized for sale by Health Canada since 2021 for the indication of endometriosis.
Media Contact
Company Name: EndoDiagnosis, Inc
Contact Person: Carolyn Plican
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hope-for-rapid-noninvasive-endometriosis-diagnosis]
Phone: 780-292-4198, 833-439-3636
Country: Canada
Website: https://endodiagnosis.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hope for Rapid, Non-Invasive Endometriosis Diagnosis here
News-ID: 3916195 • Views: …
More Releases from ABNewswire
Migraine Therapeutic Pipeline Witnesses Significant Expansion as 30+ Pharma Comp …
DelveInsight's, "Migraine Pipeline Insight 2026" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Migraine pipeline landscape. It covers the Migraine pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Migraine Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead in understanding the Migraine Treatment Landscape @ Migraine…
Obesity Clinical Trial Ecosystem Strengthens with 80+ Companies Driving Next-Gen …
DelveInsight's "Obesity Pipeline Insight 2026" report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the obesity pipeline landscape. It covers the Obesity pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Obesity therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Obesity pipeline products in this space.
Download DelveInsight's comprehensive Obesity Pipeline Report to explore emerging…
Chronic Kidney Disease Drug Development Pipeline Expands as 75+ Companies Focus …
DelveInsight's, "Chronic Kidney Disease Pipeline Insight 2026" report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in the Chronic Kidney Disease pipeline landscape. It covers the Chronic Kidney Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Kidney Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Multiple System Atrophy Clinical Pipeline Intensifies with 20+ Industry Players …
DelveInsight's "Multiple System Atrophy Pipeline Insight 2026" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Multiple System Atrophy pipeline landscape. It covers the Multiple System Atrophy Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Multiple System Atrophy Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious…
More Releases for ENDOSURE
ENDOSURE Tier 1 Endometriosis Testing Now Available in North America for First T …
Calgary, AB, Canada - June 13, 2025 - Marda Loop Wellness today announces it will become North America's first primary care clinic to offer the groundbreaking ENDOSURE test for endometriosis detection, beginning June 16, 2025. This innovative, non-invasive diagnostic tool delivers results in 30 minutes with over 99% accuracy, addressing a critical gap in women's healthcare where traditional diagnosis typically takes 8.6 years globally.
"The introduction of ENDOSURE testing represents a…
